The trial team examined circulating endocannabinoid and inflammatory markers in a small randomized, exploratory subanalysis. The study focused on whether repeated hyperbaric oxygen therapy affected serum anandamide (AEA) and lipopolysaccharide (LPS) as primary outcomes. Investigators reported this analysis as resource-limited and conducted after randomization, drawing participants from predetermined scheduling subgroups and control selections intended to improve baseline body mass index comparability.
HBOT was administered as 10 sessions performed six times weekly. Each session lasted 60 minutes at 2.5 atmospheres absolute, delivered as three 20-minute oxygen-breathing intervals separated by two 5-minute air breaks. The authors noted that fasting serum samples were obtained before and after the 10-session protocol. Biomarker quantification used enzyme-linked immunosorbent assays; the abstract did not report assay details such as manufacturer, limits of detection, or intra-assay variability.
Comparisons of change scores between the HBOT group and controls revealed no significant differences for the primary endpoints. Data indicated no statistically significant between-group change for AEA (p = 0.597) and for LPS (p = 0.885). The HBOT cohort, when assessed within-group, also showed no significant pre-to-post changes in those circulating biomarkers. The study team framed these results as exploratory and stated that the findings do not exclude the possibility of smaller effects that the current sample could not detect.
The investigators measured additional endocannabinoid-related markers as secondary or exploratory outcomes: cannabinoid receptor type 2 (CB2R) and fatty acid amide hydrolase (FAAH). Change-score comparisons between groups were non-significant for CB2R (p = 1.000) and FAAH (p = 0.885). No within-group changes in the HBOT arm were reported for those markers either. The abstract did not provide effect-size estimates, confidence intervals, or detailed assay methodology for CB2R and FAAH.
At baseline, the cohort showed a positive association between AEA and LPS. Investigators reported a Spearman correlation coefficient of 0.505 with a p value of 0.039. Authors noted this relationship as exploratory and stated that confirmation in adequately powered studies is required before inferring biological or clinical relevance.
The trial report supplied p values for primary and secondary comparisons but did not include further inferential details such as sample-size justification, power calculations, or adjustments for multiple comparisons. The randomized parent trial classification appears on record, yet this biomarker subanalysis used a post-randomization subset of 17 healthy, physically active men—9 assigned to a pre-existing frequent-treatment HBOT subgroup and 8 selected as controls. Investigators explicitly described the analysis as exploratory and resource-limited; they cautioned that non-significant results in small samples do not definitively exclude smaller or clinically meaningful effects.
The authors acknowledged key limitations tied to sample size and study design. The resource-limited, post-randomization sample and selective subgroup sourcing limit generalizability. The abstract did not provide demographic breakdowns beyond sex and general fitness status, nor did it report assay specifics or longer-term follow-up. The baseline positive correlation between AEA and LPS is an additional observation that the study team recommended verifying in larger, prospectively planned cohorts.
Remaining questions that the report leaves open include whether different HBOT pressures, session counts, or treatment schedules would affect circulating endocannabinoid markers, and whether patient populations with baseline inflammation or disease would respond differently. The abstract closes with a clear, narrowly framed conclusion: receiving 10 sessions of HBOT was not associated with significant changes in the measured circulating biomarkers in this small sample, and the baseline AEA–LPS association requires confirmation in adequately powered studies.